weight-lossclinical-trials
CagriSema
CagriSema (Semaglutide + Cagrilintide)
Overview
A next-generation combination therapy by Novo Nordisk combining semaglutide with cagrilintide (an amylin analogue). Aims for even stronger weight loss effects than Wegovy alone.
Mechanism of Action
Dual mechanism: semaglutide activates GLP-1 receptors while cagrilintide mimics amylin, a hormone that slows gastric emptying and promotes satiety. The combination provides enhanced appetite suppression.
Popular Research Uses
- Weight loss (investigational)
- Enhanced appetite control
- Obesity treatment
Potential Side Effects
- Nausea (likely more common)
- Vomiting
- Diarrhea
- Constipation
- Unknown - trials ongoing
Warnings
- NOT FDA approved - still in clinical development
- Approval timeline remains uncertain pending trial and regulatory outcomes
- No gray market versions available
- May have enhanced side effects vs single agents
- Unknown long-term effects
Dosage Information
Combination of two proven mechanisms. Wait for FDA approval and proper medical guidance.